A pilot study to assess the awareness of herpes
zoster and the attitudes towards herpes zoster
vaccination among Chinese patients attending
a government general out-patient clinic in
Hong Kong
Long-yee Cheng 鄭朗兒
HK Pract 2019;41:60-65
Summary
Objective:
Herpes zoster (HZ) is a common disease encountered
in primary care.
This survey studied:
(1) Chinese patient’s awareness and knowledge of
herpes zoster
(2) The factors associated with a positive attitude
towards having the herpes zoster vaccination
(3) Barriers to accepting vaccination against herpes
zoster
Subjects:
400 patients aged 50 or above recruited
from a government general out-patient clinic.
Design: A cross sectional questionnaire-based survey.
Main Outcome measures:
Responses on awareness,
personal history, and knowledge about HZ, and
reasons for accepting or refusing HZ vaccination, and
demographic information.
Results:
The awareness of HZ was high but vaccination
acceptance among our subjects was low.
Factors that were significantly associated with a higher
acceptance of vaccination included a personal history
of HZ, and having history of influenza vaccination in
the past 2 years. The commonest reason for subjects
to accept vaccination was “concerned about HZ
complications”.
Conclusions:
Health education is an important step to
introduce to the general public about the disease, and the complications of HZ. If people know more about
the burden of complications, they may be more willing
to be vaccinated.
Health care providers’ recommendation of the vaccine
is also important.
Keywords:Herpes zoster, vaccination, knowledge,
acceptance, primary care
摘要
目的:帶狀皰疹是一種基層醫療常見的疾病。本調查研究:
1. 中國籍病人對帶狀皰疹的意識和知識。
2. 對帶狀皰疹疫苗採取正面態度的相關因素。
3. 接受帶狀皰疹疫苗注射的障礙。
研究對象:一所政府普通科門診內400位50歲或以上的病人。
設計:橫斷面問卷調查。
主要測量內容:調查回應研究對象關於帶狀皰疹的意識、個人病歷和知識,接受或拒絕帶狀皰疹疫苗的原因,以及人口統計學的資料。
結果:研究對象對帶狀皰疹有高意識,但疫苗接受程度低。較高疫苗接受程度的重要相關因素包括曾罹患帶狀皰疹的個人病歷和過去兩年曾接種流感疫苗的病歷。研究對象接受疫苗最常見的原因是「擔心帶狀皰疹引致的併發症」。
結論:健康教育是向公眾介紹帶狀皰疹的發病過程和 併發症的重要一步。假如人們認識多一點併發症的煩擾,他們可能更願意接受疫苗注射。醫護人員對疫苗的推薦亦很重要。
關鍵字:帶狀皰疹、疫苗、知識、接受、基層醫療。
Introduction
Herpes zoster (HZ), also known as shingles, is a
reactivation of the latent Varicella zoster virus infection
in the sensory nerve ganglion. Post herpetic neuralgia
(PHN) is a common and severe complication which can
persist for months to years.1
There are more than 1 million new cases of HZ
in the United States every year and the risk of HZ
increases with age.2
The lifetime risk of developing HZ is between 25%
and 30%, rising to 50% in those aged over 80 years.15-17
A study analysed the incidence of HZ from 12 countries
in Asia-Pacific, Europe, North America and Middle-east.
The estimated overall incidence is about 3.4 - 4.82
per 1,000 person-years which increases to over 11 per
1,000 person-years in those aged at least 80 years.17
In 2013, the Public Opinion Programme of The
University of Hong Kong conducted a telephone
interview about HZ Vaccination targeting Cantonese-speaking
local citizens in Hong Kong of age 50 - 80.
Out of 2,042 subjects, 344 (16.8%) recalled a previous
history of herpes zoster.18
About 10 - 25% of patients infected with HZ
virus will have complications such as PHN and HZ
ophthalmicus.3 In Asia-Pacific region such as Taiwan
and Korea, severe morbidity, and significant healthcare
resource utilisation, are also observed to be associated
with HZ, supporting the need for preventive strategies
to reduce the burden of illness.9,10
The HZ vaccine was licensed in 2006. In 2011, the
US Food and Drug Administration approved the use of
this vaccine for adults >50 year-old.1
The HZ vaccine reduces the risk of having HZ
by 51%.6 It can reduce the burden of illness and the
incidence of PHN by 61% and 67% respectively.2,4,6
Although the HZ vaccine is known to be effective to
decrease the risk and burden of HZ, vaccination rates
have remained low. In 2011, the vaccination rate among
adults aged 60 or older was only 15.8% in the US.3 A
few studies have assessed the factors associated with
and obstacles to HZ vaccination status. Factors that
have been found to play a role in influencing patient
attitudes towards the vaccine include knowledge on HZ,
physician’s recommendation, information from the mass
media and history of previous influenza vaccination.1-4
This vaccine was registered in Hong Kong in
2007.7 Currently, there is a lack of information about
the awareness and degree of acceptance of the herpes
zoster vaccine and the factors influencing patient
attitudes towards HZ vaccination in Hong Kong. This
study aims to fill this gap in knowledge and to help
inform doctors on how their patients can be educated to
enhance the HZ vaccine uptake in our setting.
Methods
Population
A convenient sample of patients aged 50 or above
was identified and recruited by the principal investigator
from a government outpatient clinic in Hong Kong East
Cluster between May and July 2016. Patients who were
illiterate, who had debilitating psychiatric diseases,
or who were in a mental state that was not capable of
giving informed consent were excluded. Data collected
did not contain protected health information or patient
identifiers. The study was approved by the Hong Kong
East Cluster Research Ethics Committee.
Study design and Measurements
A structured questionnaire was developed by the
principal investigator after taking similar studies on
vaccination as references.1, 3-5, 11-14 Some of the questions
were adopted from the framework of the Health Belief
Model (HBM) about perceived susceptibility, perceived
benefits, barriers and cues to action. The HBM has
been widely used in different studies to identify
patients’ perceptions of disease and vaccination.11-13
Clinic supervisors were invited to check the relevance
and comprehensibility of the questionnaire by testing
on clinic patients prior to using it on the study
subjects. Face-to-face interviews were conducted after
the subjects signed the consent form. The interviews
took about 10 minutes to complete. Part one of the
questionnaire was designed to gather information on
the awareness of HZ, knowledge about HZ, previous
history of health care provider’s recommendation on HZ
vaccination and attitudes towards acceptance of the HZ
vaccination.
Reasons for or against receiving HZ vaccination
were asked depending on the participants’ answers on
the acceptance of vaccine. Knowledge about HZ was
assessed by asking 6 questions with choices of “Yes”,
“No” and “Do not know”. The questions were about
the pathology, symptomatology, Chinese myths and
complications of HZ.
Participants who were not aware of HZ at all were
asked to skip the remaining questions of Part one and
answer Part two directly.
Part two of the questionnaire assessed patient’s
sociodemographic factors, history of influenza
vaccination in the past two years and personal history
of diabetes or cancer.
Statistical methods
The survey data were analysed with IBM SPSS
Version 24.0. Chi-square test was used to examine
the differences in the effect of demographic factors,
knowledge score, past experiences of HZ, past
recommendations of HZ vaccination from a health
care provider and the acceptance of the HZ vaccine.
Univariate logistic regression was used to assess each
variable for their associations with attitudes towards HZ
vaccination. Multivariate logistic regression was used
to examine the attitudes towards HZ vaccination while
controlling all sociodemographic factors, knowledge
score, recommendation from Health care providers and
personal experience on HZ. The cut-off for statistical
significance was set at p<0.05.
Results
Sample characteristics
A total of 400 Chinese participants aged 50 or
above were recruited in the research. None were
excluded. Table 1 shows the demographic characteristics
and HZ awareness of the respondents. The sample
consisted of 185 men (46.2%) and 215 women (53.8%)
aged 50 to 89 years (mean age, 65 years). Almost half
of the participants (48.5%) were in the 60-69 year-old
age group. As the common retirement age in Hong
Kong is 60-year-old, 57.2% of the participants reported
unemployed and 69.3% of participants were having
monthly household income of less than $15,000. With
respect to educational level, 52.2% of participants
reached secondary school level, and 16% reached
tertiary level. As the clinic was located in the Wan
Chai district, most of the participants lived on Hong
Kong Island (71.2%) and private building (71.2%).
Awareness of HZ
Participants were asked if they had ever heard of
HZ; 95.2% stated that they were aware of HZ (n=381),
24.5% of the participants had a history of HZ, 60.8% of
the participants knew of someone with HZ.
Knowledge of HZ and its vaccination
Of the 381 participants who were aware of HZ,
their knowledge, acceptance of HZ vaccination and the
reason(s) behind their attitude towards HZ vaccination
were assessed. In the knowledge test, only 14.4%
answered all the six questions correctly (Table 2). Most
knew the symptoms of HZ (91.9%), however, there was
deficiency in the knowledge on PHN and pathology of
HZ. (Figure 1)
Only 9.4% had been previously introduced to HZ
vaccination by health care providers.
Acceptability of HZ vaccine
Among the 381 subjects who were aware of HZ
infection, over half of them refused vaccination (54.3%),
while 42.5% were agreeable to having the vaccination if
asked. Only 12 participants had previously received the
vaccination.
Univariate logistic regression analysis showed that
personal history of HZ, better knowledge on HZ, and
history of influenza vaccination in the past 2 years
were significantly and positively associated with a
willingness to receive the vaccination (Table 3).
On multivariate logistic regression , after
controlling all demographic factors, knowledge score
and HZ awareness variables, only personal history of
HZ, and history of influenza vaccination in the past
2 years remained as significant factors. Those with
personal history of HZ were 1.76 times more likely to
accept vaccination (95% CI, 1.05~2.97) whilst those
with history of influenza vaccination in the past 2
years were 2.5 times more likely to receive vaccination
for HZ (95% CI, 1.55~4.05). Chronic illness such as
diabetes or cancer were not shown to be significantly
associated with the acceptance of the vaccine.
Reasons for acceptance
Respondents who were agreeable to receiving the
vaccination were asked why they wanted to have the
vaccination (Table 4). The most common answer was
“concerned about HZ complications” (84.5%), followed
by “Health care provider recommendations” (56.9%),
“Reasonable price” (29.3%), “the vaccine is effective”
(24.1%), a nd “Family/friends recommendations”
(15.5%). A small number of participants responded with
“Commercial advertisement” (9.2%).
Reasons for refusal of vaccination
The most common reason underlying a refusal
to the vaccination was “No perceived risk of getting
herpes zoster” (51.7%), followed by “Afraid of vaccine
side effect” (50.7%), “Doubt on vaccine effectiveness”
(28%), “No recommendation from health care providers”
(27.5%), and “Too expensive” (21.3%) (Table 5).
Discussion
In the present study, we investigated the awareness
of HZ, knowledge about HZ and its vaccine, and the
HZ vaccination acceptance and the reason for and
against injection among 400 participants attending a
general outpatient clinic in Wan Chai district. We also
analysed the factors which predicted HZ vaccination.
Among our sample, 24.5% of all respondents had a
history of HZ. This rate is higher than a local telephone
survey (16.8%).18This prevalence is similar to a study
conducted in Korea4.
Although there was evidence that HZ vaccination
is effective in reducing the incidence of HZ and PHN,
only 12 out of the 381 participants had been previously
vaccinated. The overall acceptance rate towards HZ
vaccination in this study was 45.7%. It is slightly lower
than the influenza vaccination acceptance rate (49.3%)
conducted in a local study.11
Among the respondents who claimed they were
aware of HZ, knowledge on HZ was just average,
with only 72.4% answering 3 or more questions out
of 6 correctly. In the unadjusted analysis, the group
with higher knowledge scores had a 1.92-times higher
vaccination acceptance (p=0.006) (95%CI, 1.20-3.05).
Although the association became less significant in the
adjusted analysis (p=0.059), it seems that efforts should
be made on education about HZ and its vaccination if
we hope to increase the vaccine uptake.
We found that the HZ vaccine acceptance rate was
2.5 times higher in patients with a history of influenza
vaccination the past 2 years (95% CI, 1.55-4.05). This
positive association was also shown by other studies.2,3,14
One possible explanation is that this group of patient
are more proactive in preventive care.14
Having a history of HZ was also a positive factor
associated with the acceptance of HZ vaccination.
The acceptance rate was 1.76 times higher (95% CI,
1.05-2.97). It seems that the fear or experience of HZ
complications may have increased the demand for
vaccination among these patients.
The most common reason given in our study for
not having the HZ vaccination was that there was no
perceived risk of getting HZ (51.7%). The surveyed
patients also reported concern on the side effects
of the vaccine (50.7%). Other reasons for refusal of
vaccination included “Doubt on vaccine effectiveness”
(28%). These reasons were also reflected in research
in other developed countries. 2,5 It seemed that our
participants had misconceptions about HZ and the
effectiveness of the vaccine, which was reflected in the
knowledge test results.
There were several limitations to this study. Firstly,
data was collected by self-report, thus the past history
of herpes zoster or history of vaccination could not be
verified and might be at risk of recall bias. Secondly,
we selected patients who visited the GOPC in Wan
Chai, so most of the participants in this study lived
in urban areas. Larger studies are needed in future
to recruit participants in different districts for a more
accurate estimation of prevalence, vaccination rates and
attitudes to the vaccine to enable better generalisability.
Thirdly, the design of this survey was based on a
literature review but further testing is needed to ensure
the validity and reliability of the results.
Conclusion
To date, there has been only a few studies
conducted in HK to investigate the attitudes of patients
towards HZ vaccine. Knowing the reasons for or
against vaccination can help inform the government or
health care providers on what information is needed to
educate the public about HZ and promote uptake of the
vaccine.
From our study findings, it appears that greater
public health education on safety and efficacy of
the HZ vaccination is still needed and that there are
common misconceptions that need to be addressed and
corrected. Recommendation by health care providers
appears to be an important influencing factor to
enhance vaccination rates. Health care providers should
seize the opportunity to promote HZ vaccination when
patients attend for their influenza vaccination.
Acknowledgement
No sources of funding were used to assist in the
work of this research. Author disclosed no conflict of
interest.
The author gratefully acknowledged Dr Wong Man
Ying, Michelle, Dr Tsui Pun Nang and Dr Leung Pui
Sha, Crystal from the Department of Family Medicine
and Public Health Care, Hong Kong East Cluster for
their advice and support.
Long-yee Cheng,MBBS (HKU), FRACGP, FHKCFP, Diploma of Child Health (Sydney)
Resident,
Department of Family Medicine, New Territories East Cluster, Hospital Authority
Correspondence to:Dr Long-yee Cheng, Fanling Family Medicine Centre, 1/F,
Fanling Health Centre, Hong Kong SAR.
E-mail: cly710@ha.org.hk
References:
-
Lee TJ, Hayes S, Cummings DM, et al. Herpes zoster knowledge, prevalence,
and vaccination rate by race. J Am Board Fam Pract. 2013;26(1):45-51.
-
Lu PJ, Euler GL, Harpaz R, et al. Herpes zoster vaccination among adults
aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1-e6.
-
Teeter BS, Garza KB, Stevenson TL, et al. Factors associated with herpes
zoster vaccination status and acceptance of vaccine recommendation in
community pharmacies. Vaccine. 2014;32(43):5749-5754
-
Roh NK, Park YM, Kang H, et al. Awareness, knowledge, and vaccine
acceptability of herpes zoster in Korea: A multicenter survey of 607
patients. Ann Dermatol. 2015;27(5):531.
-
Mortensen GL. Perceptions of herpes zoster and attitudes towards zoster
vaccination among 50-65-year-old Danes. Dan Med Bull. 2011;58(12):A4345.
-
Ox man M N, Levin MJ, Joh nson GR, et al. A vaccine to prevent
herpes zoster and postherpetic neuralgia in older adults. N Engl J Med.
2005;352:2271-2284.
-
Compendium of pharmaceutical products, 2016. Drug Office, Department of
Health, The Government of the Hong Kong Special Administrative Region.
-
FDA approves Zostavax vaccine to prevent shingles in individuals 50 to
59 years of age. US Food and Drug Administration. 2011. Available from:
https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/
ucm136941.htm [accessed 2017 December 10]
-
Tsai TF, Yao CA, Yu HS, et al. Herpes zoster-associated severity and duration
of pain, health-related quality of life, and healthcare utilization in Taiwan: a
prospective observational study. Int J Dermatol. 2015;54(5):529-536.
-
Song H, Lee J, Lee M, et al. Burden of illness, quality of life, and healthcare
utilization among patients with herpes zoster in South Korea: a prospective
clinical-epidemiological study. Int J Infect Dis. 2014 Mar;20:23-30.
-
Mo PKH, Lau JTF. Influenza vaccination uptake and associated factors
among elderly population in Hong Kong: the application of the Health
Belief Model. Health Educ Res. 2015 Oct;30(5):706-718.
-
Lyn-Cook R, Halm EA, Wisnivesky JP. Determinants of adherence to
influenza vaccination among inner-city adults with persistent asthma. Prim
Care Respir J. 2007 Aug;16(4):229-235.
-
Coe AB, Gatewood SBS, Moczygemba LR, et al. The use of the health
belief model to assess predictors of intent to receive the novel (2009) H1N1
influenza vaccine. Inov Pharm. 2012;3(2):1-11.
-
Javed S, Javed F, Mays RM, et al. Herpes zoster vaccine awareness among
people >50 years of age and its implications on immunization. Dermatol
Online J. 2012 Aug 15;18(8):2.
-
Studahl M, Petzold M and Cassel T. Disease burden of herpes zoster in
Sweden - predominance in the elderly and in women - a register based
study. BMC Infect Dis. 2013 Dec 12;13:586.
-
Yawn BP and Gilden D. The global epidemiology of herpes zoster.
Neurology. 2013 Sep 3;81:928-930.
-
Robert WJ, Alvarez - Pasquin MJ, Bijl M ,et al.Herpes zoster
epidemiology, management, and disease and economic burden in Europe: a
multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109-120.
-
Survey on herpes zoster vaccine. The Public Opinion Programme (POP) of
The University of Hong Kong. 2013. Available from: https://www.hkupop.
hku.hk/english/report/prppl/index.html#6 [accessed: 2017 December 10]
|